Lupin and Tenpoint Therapeutics Form Strategic Partnership for YUVEZZI™ in Europe and Beyond

Strategic Partnership Announced for YUVEZZI™ Marketing in Europe

In a significant move within the pharmaceutical industry, Lupin Limited, a prominent global pharmaceutical company, has entered into a strategic partnership with Tenpoint Therapeutics. This alliance is aimed at marketing and commercializing the unique presbyopia treatment, YUVEZZI™, across key regions in Europe including the European Union, the United Kingdom, Switzerland, Norway, and Iceland. This partnership highlights the companies' commitment to expanding access to innovative eye care solutions for patients worldwide.

A Game-Changer in Eye Care

YUVEZZI™ stands out in the marketplace as the first and only eye drop solution that combines two active ingredients to treat presbyopia, a condition typically affecting individuals around the age of 45 who experience a gradual decline in near vision. The formulation, which consists of Carbachol and Brimonidine Tartrate, is designed for once-daily use, making it a convenient option for users.

Through this strategic collaboration, VISUfarma B.V., a 100% subsidiary of Lupin, has secured exclusive rights to handle the regulatory processes, marketing, distribution, and sales of YUVEZZI™ in the specified territories. This also includes a strategic investment from VISUfarma into Tenpoint, which allows for milestone payments contingent on regulatory and marketing achievements and tiered royalties based on net sales.

Strengthening Market Presence

Vinita Gupta, CEO of Lupin, expressed enthusiasm about collaborating with Tenpoint Therapeutics to bring this innovative ophthalmic treatment to market. She emphasized how this partnership aligns with Lupin’s strategy to enhance their specialty care portfolio while further solidifying their presence in critical European markets. By integrating YUVEZZI™ into their offerings, Lupin aims to expand access to differentiated therapies that can improve treatment outcomes for patients.

Henric Bjarke, CEO of Tenpoint, noted that this partnership is essential for fulfilling their mission to make YUVEZZI™ available to millions of patients suffering from presbyopia and eye care professionals worldwide. He highlighted Lupin's established sales infrastructure and VISUfarma’s long-standing expertise in ophthalmology as key factors that make Lupin a valuable collaborator.

Broader Impact on Presbyopia Management

The introduction of YUVEZZI™ represents not just a new product but also a broader effort to address the unmet needs of patients with presbyopia. Tenpoint is already advancing the marketing and approval of YUVEZZI™ in the United States following its recent FDA approval. The partnership aims to increase the product’s reach through various regional collaborations, including an ongoing registration application with the UK’s MHRA (Medicines and Healthcare products Regulatory Agency).

As part of its commitment to healthcare innovation, Lupin is continually enhancing its portfolio by incorporating targeted therapies that address crucial healthcare challenges. The strategic partnership with Tenpoint Therapeutics is a step towards fulfilling this objective and reinforcing its position in the ophthalmic sector.

About the Companies

Lupin Limited is a leading global pharma firm based in Mumbai, India, recognized for its strong market presence across various geographies including the US and other developed and emerging markets. The company’s diversified portfolio encompasses generics, specialty drugs, and biosimilars, with a focus on key therapeutic areas like cardiovascular health, respiratory disorders, diabetes, and women's health. With a robust workforce of over 26,000 professionals and advanced manufacturing facilities, Lupin aims to broaden its healthcare ecosystem through digital health, diagnostics, and patient support initiatives.

Tenpoint Therapeutics, on the other hand, specializes in the ophthalmic market, focusing on innovative solutions for ocular conditions. They are dedicated to developing effective therapies through collaboration with eye care professionals, addressing the requirements of an aging population susceptible to vision issues. YUVEZZI™ is particularly vital as it offers a practical solution for a condition that impacts approximately 2 billion people worldwide.

For additional information on YUVEZZI™, patients and healthcare professionals can visit the specialized website, ensuring they access the latest data about this promising new eye treatment.